BOSTON ( TheStreet) -- Congratulations to the three winners of TheStreet's FDA Drug Approval Contest. Each compiled impressive 10-1 records correctly predicting FDA drug approvals and rejections during the busy month of October.

The winners:

BioTrekker: A professional healthcare investor (yes, he works at a hedge fund!) whose only miscue was incorrectly predicting an FDA delay for Avanir Pharmaceuticals' ( AVNR) Nuedexta. For compliance reasons, BioTrekker asked not to be identified by his real name.

Superrfly: Also known as Matthew Wenzlick, a 21-year-old college student majoring in finance. Wenzlick has been trading stocks since January 2009 and has gradually shifted his focus towards the biotech sector. "Superrfly" didn't start off the contest so super, he got the Hospira ( HSP) decision wrong at the top of October, but he was perfect after that.

Our third winner, Joe, remains behind a curtain. Joe didn't respond to my email informing him of his good fortune, so perhaps he's just shy. Joe may not want to be identified but I can still congratulate him for an almost-perfect drug approval prediction record. His only blemish was incorrectly predicting the rejection of Forest Labs' ( FRX) antibiotic.

To quickly recap the contest, these three winners beat out 91 other contestants in correctly guessing the outcome of 11 FDA drug approval decisions in October. What's most impressive about BioTrekker, Superrfly and Joe is that they were among only a handful of contestants who correctly predicted the FDA's rejection of Amylin Pharmaceuticals' ( AMLN) diabetes drug Bydureon. To me, that decision was the biggest surprise of the month and it was the turning point for the contest.

Guessing right on the Alkermes ( ALKS) approval or the rejections handed to Vivus ( VVUS) and Arena Pharmaceuticals ( ARNA) was fairly easy, but nailing the tough-to-call outcomes like Avanir and Alexza Pharmaceuticals ( ALXA) showed true skill.

BioTrekker came oh-so close to running the table and being the sole contest winner because he tells me he was leaning positive on Avanir.

How did our winners manage to go 10-1?

"You have to do research independent of the companies and sell-side analysts," says BioTrekker. "Reading press releases is not due diligence. There is a lot of information to be found on the Internet. Use Google, but go beyond the first page of search results.

"Run down obscure things. A lot of drugs are old and repurposed. Management teams and companies often have histories they don't necessarily want you to know about. Be a skeptic," he adds.

Superrfly i.e. Wenzlick says he pays attention to whether a drug is unique and targets a large market. "While harder to obtain approval, the unique drugs seem to be the biggest moneymakers for investors."

If you liked this article you might like

Develop Biotech 'Buy-Sell' Strategy

Develop Biotech 'Buy-Sell' Strategy

Two Small-Cap Biotechs To Consider

Two Small-Cap Biotechs To Consider

Next Year's Stock Returns: 5% or 15%?

Next Year's Stock Returns: 5% or 15%?

Updating a Small Speculative Play

Updating a Small Speculative Play

Three Large-Cap Growth Stocks

Three Large-Cap Growth Stocks